CoChat

CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses

Open access
Cheng, Hung-Wei, Onder, Lucas, Cupovic, Jovana, Boesch, Maximilian, Novkovic, Mario, Pikor, Natalia, Tarantino, Ignazio, Rodriguez, Regulo, Schneider, Tino, Jochum, Wolfram, Brutsche, Martin, Ludewig, Burkhard · 2018 · Journal of Allergy and Clinical Immunology
Cited by 89

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background A particular characteristic of non–small cell lung cancer is the composition of the tumor microenvironment with a very high proportion of fibroblastic stromal cells (FSCs). Objective Lapses in our basic knowledge of fibroblast phenotype and function in the tumor microenvironment make it difficult to define whether FSC subsets exist that exhibit either tumor-promoting or tumor-suppressive properties. Methods We used gene expression profiling of lung versus tumor FSCs from patients with non–small cell lung cancer. Moreover, CCL19-expressing FSCs were studied in transgenic mouse models by using a lung cancer metastasis model. Results CCL19 mRNA expression in human tumor FSCs correlates with immune cell infiltration and intratumoral accumulation of CD8 + T cells. Mechanistic dissection in murine lung carcinoma models revealed that CCL19-expressing FSCs form perivascular niches to promote accumulation of CD8 + T cells in the tumor. Targeted ablation of CCL19-expressing tumor FSCs reduced immune cell recruitment and resulted in unleashed tumor growth. Conclusion These data suggest that a distinct population of CCL19-producing FSCs fosters the development of an immune-stimulating intratumoral niche for immune cells to control cancer growth.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2017.12.998

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 89

Metadata

Authors
Cheng, H.-W., Onder, L., Cupovic, J., Boesch, M., Novkovic, M., Pikor, N., Tarantino, I., Rodriguez, R., Schneider, T., Jochum, W., Brutsche, M., & Ludewig, B.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2018-10
Volume
142
Issue
4
Pages
1257-1271.e4
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2786405849
Cited by
89
References
14
FWCI
2.36
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses. https://app.cochat.ai/papers/10.1016/j.jaci.2017.12.998
The paper
Cheng, H.-W., Onder, L., Cupovic, J., Boesch, M., Novkovic, M., Pikor, N., Tarantino, I., Rodriguez, R., Schneider, T., Jochum, W., Brutsche, M., & Ludewig, B. (2018). CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2017.12.998

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.